Blog

This year, seven of Pacific Neuroscience Institute’s physicians were included in Los Angeles Magazine’s April 2021 roster of “L.A.’s Top Doctors.” The results were based on a Los Angeles Magazine survey that asked physicians throughout Los Angeles County to identify the doctors they considered to be at the...

Now twenty-one years in remission from a pituitary adenoma tumor, Sharmyn McGraw, patient advocate, author, artist, and so much more, talks about the pivotal role of Cushing’s disease in her life. From dyslexia to writer and everything in between. Dealing with a life threatening disease,...

PNI’s Year-in-Review 2020 was, despite the pandemic, a strong year for clinical care delivered by PNI providers with multiple milestones being achieved.  We’ve entered 2021 with a deep commitment to treating our patients at our ten centers of excellence, doing groundbreaking research, providing innovative clinical...

Although our medical community continues to strain under the burden of COVID-19, there has been hope, determination and progress. Neurological diseases do not stop and neither have we at Pacific Neuroscience Institute.

New Studies Blue Earth Diagnostics FLC-219: (PDF): An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy (PURSUE) (NCT04410367) Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A...

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Nineteen of PNI’s doctors have been recognized as Super Doctors in the 2021 announcement of this prestigious industry standard award. Of note, Daniel F. Kelly, MD, Founder and Director of PNI, and expert neurosurgeon became a Hall of Fame Super Doctor. With his selection to...

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience ( PDF ): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma ( NCT03463265 ) Orbus Therapeutics ( PDF ): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

The Think Neuro podcast from Pacific Neuroscience Institute takes you into the clinic, operating room and laboratory with doctors and surgeons who are tackling the most challenging brain diseases and disorders. Host: Anthony Effinger Subscribe: Google Podcasts | Apple Podcasts | Spotify | Simplecast Watch: YouTube Episode 6: Show Notes When patients ask him...